2-(Piperidin-1-yl)pyrimidine-4,6-diamine → 2-Phenyl-5-piperidin-1-yl-imidazo[1,2-c]pyrimidin-7-ylamine
반응식
[N:1]1([C:7]2[N:12]3[CH:13]=[C:14]([C:16]4[CH:21]=[CH:20][CH:19]=[CH:18][CH:17]=4)[N:15]=[C:11]3[CH:10]=[C:9]([NH2:22])[N:8]=2)[CH2:6][CH2:5]O[CH2:3][CH2:2]1.N1(C2N=C(N)C=C(N)N=2)CCCC[CH2:24]1>>[C:16]1([C:14]2[N:15]=[C:11]3[CH:10]=[C:9]([NH2:22])[N:8]=[C:7]([N:1]4[CH2:6][CH2:5][CH2:24][CH2:3][CH2:2]4)[N:12]3[CH:13]=2)[CH:21]=[CH:20][CH:19]=[CH:18][CH:17]=1참가 물질
3
실험 절차
The title compound was prepared in analogy to 5-morpholin-4-yl-2-phenyl-imidazo[1,2-c]pyrimidin-7-ylamine (Example 63, Step 1) from 2-piperidin-1-yl-pyrimidine-4,6-diamine. MS (m/e)=294.2 [M+H+].
출처 및 근거
- ORD 기록
- ord-9f3db1a42cec4acf95b141af0b697c8f
- 출처 데이터셋
- uspto-grants-2011_09
- 특허 번호
- US08017604B2
반응 노트
불러오는 중…